EUCTR2007-005891-15-IT进行中（未招募）不适用
A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events including Bleeding and Symptomatic Ulcer Disease - COGENT-1, Clopidogrel and the Optimization of Gastrointestinal Events
COGENTUS PHARMACEUTICALS INTERNATIONAL LIMITED0 个研究点目标入组 3,200 人开始时间: 2008年5月16日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 3,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria: Patients must meet all inclusion criteria Patients in whom a requirement for clopidogrel therapy with concomitant aspirin is anticipated for at least the next 12 months. Specific conditions that may confer a need for long-term clopidogrel + aspirin therapy may include non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI), ST segment elevation acute MI), or new placement of a coronary artery stent. Age ≥ 21 years. No more than 40% of participants will be less than 65 years of age at randomization. For women of childbearing potential, negative pregnancy test prior to randomization and agreement to use effective method of birth control during the study. Able to provide written informed consent based on competent mental status.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria: Any of the criteria will result in exclusion Patients who are currently hospitalized for whom discharge is not anticipated within 48 hours of randomization. Requirement for current or chronic use of a proton pump inhibitor, H2 receptor blocker, sucralfate or misoprostol. Erosive esophagitis, esophageal or gastric variceal disease, or non-endoscopic gastric surgery. Patients with a history of GERD/erosive esophagitis or dyspepsia who do not currently require proton pump blockers will be eligible. Receipt of > 21 days of clopidogrel or another thienopyridine prior to randomization. Oral anticoagulation with warfarin that cannot be safely discontinued for duration of study. Recent fibrinolytic therapy (for fibrin-specific and nonfibrin-specific agents, administration < 24 hours and < 48 hours before randomization, respectively). Scheduled percutaneous coronary intervention (PCI). Patients may be enrolled upon completion of PCI. Recent (< 30 days prior to randomization) or scheduled coronary artery bypass graft (CABG) surgery. Cardiogenic shock at the time of randomization, refractory ventricular arrhythmias, or congestive heart failure (New York Heart Association class IV). Active pathological bleeding or a history of hereditary or acquired hemostatic disorder. History of hemorrhagic stroke, intracranial neoplasm, arteriovenous malformation or aneurysm. Platelet count < 100,000/mL at screening. Anemia (hemoglobin < 10 g/dL) at screening. Systemic corticosteroids except low-dose oral corticosteroids equivalent to prednisone ≤ 5 mg/day. Allergy or contraindication to clopidogrel or other thienopyridine drugs, omeprazole or other proton pump inhibitor drugs, aspirin or salicylate derivatives, or other study drug ingredients. Treatment within 30 days prior to randomization with any investigational drug or device including investigational (not approved) coronary artery stents, or currently enrolled in another interventional drug or device study. Women who are pregnant or breastfeeding. Life expectancy less than 12 months. Clinically significant laboratory abnormality at screening or any other condition that, in the opinion of the Investigator, precludes participation in the study.
研究者
相似试验
进行中（未招募）
1 期
A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple SclerosisEUCTR2010-020337-99-SKF.Hoffmann-La Roche821
进行中（未招募）
1 期
A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple SclerosisRelapsing Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-020337-99-ATF.Hoffmann-La Roche821
已完成
3 期
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple SclerosisAutoimmune disorder of the central nervous system10007951MSNL-OMON43603Hoffmann-La Roche1
进行中（未招募）
1 期
A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple SclerosisRelapsing Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-020337-99-BGF.Hoffmann-La Roche821
进行中（未招募）
不适用
A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple SclerosisRelapsing Multiple SclerosisMedDRA version: 14.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-020337-99-ESF.Hoffmann-La Roche800